Revelation Biosciences Files 8-K, Details Financials
Ticker: REVBW · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $12,075.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-history, financial-statements
Related Tickers: REVB
TL;DR
REVB filed an 8-K on 9/27 for a 9/24 event, showing financials and former name Petra Acquisition Inc.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on September 27, 2024, reporting an event on September 24, 2024. The filing indicates the company's former name was Petra Acquisition Inc., with a name change on April 23, 2020. The report details financial statements and exhibits.
Why It Matters
This filing provides an update on Revelation Biosciences' financial reporting and corporate history, which is important for investors to understand the company's current status and past changes.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- Petra Acquisition Inc. (company) — Former company name
- April 23, 2020 (date) — Date of name change
- September 24, 2024 (date) — Earliest event date reported
- September 27, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Revelation Biosciences, Inc.?
The primary purpose is to report on Other Events and to file Financial Statements and Exhibits as of September 24, 2024.
What was Revelation Biosciences, Inc. previously known as?
Revelation Biosciences, Inc. was formerly known as Petra Acquisition Inc.
When did the company change its name from Petra Acquisition Inc.?
The company changed its name on April 23, 2020.
What is the Commission File Number for Revelation Biosciences, Inc.?
The Commission File Number for Revelation Biosciences, Inc. is 001-39603.
What is the business address of Revelation Biosciences, Inc. as listed in the filing?
The business address is 4660 La Jolla Village Drive, Suite 100, San Diego, California, 92122.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-09-27 16:09:26
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma
Filing Documents
- revb-20240924.htm (8-K) — 43KB
- revb-ex99_1.htm (EX-99.1) — 27KB
- img220778470_0.jpg (GRAPHIC) — 18KB
- img220778470_1.jpg (GRAPHIC) — 58KB
- 0000950170-24-109998.txt ( ) — 331KB
- revb-20240924.xsd (EX-101.SCH) — 48KB
- revb-20240924_htm.xml (XML) — 7KB
01 Other Events
Item 8.01 Other Events. On September 24, 2024, Revelation Biosciences, Inc. (the "Company") issued a press release titled "Gemini Induces Dose Dependent Significant Increases in IL-10". A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 24, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: September 27, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)